Pfizer's new acquisition generates billions of dollars from migraine drug

The biotech firm’s migraine drug soared in the latest quarter – even though Pfizer’s acquisition deal has not been finalized.

Photo: Mark Lennihan/AP/Ritzau Scanpix

Biohaven, which was acquired by Pfizer for USD 11.6bn in May though the deal won’t be finalized until early 2023, has just released its financial figures for the second quarter reporting soaring sales of migraine drug Nurtec, booking a 57% growth compared to last quarter, industry media Endpoints News reports.

Bringing in a revenue of USD 194m in Q2, Biohaven says progress is mostly due to more prescriptions for oral Nurtec ODT and ”favorable pack mix per prescription.” Nurtec ODT was approved by the US Food and Drug Administration (FDA) in February, 2020, as a treatment of acute migraines and was later authorized as a preventive treatment, in May 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs